Litigation-healthcare partner Andy Ruskin will present on a panel titled “Overcoming New and Evolving Challenges in the Pricing of Specialty Products” at the ACI’s 18th Annual Rx Drug Pricing Master Class.
Topics will include:
What qualifies as a specialty pharmaceutical, and how are they different from other drugs?
What are some of the factors considered when pricing a specialty product?
Evaluating the EpiPen hearings and their impact on pricing
The impact of Trump’s White Paper and any implementation thereof on SP products
Adhering to HRSA’s 340B requirements with respect to limited distribution drugs
Choosing a specialty pharmacy distribution chain, a buy and bill distribution chain, or both
Rules regarding “bridge” programs
What are the pricing and contracting compliance issues that exist in personalized medicine and gene therapies?
Discussing bills at the federal and state levels in relation to opioids
What theories are states using against opioid manufacturers that effect pricing?
The recent tax in New York on opioids within the state
What other states are planning to tax the product?
Exploring the rising prices on opioid inhibiting drugs
What are the evolving pricing risks going forward?